Brainstorm Cell Therapeutics (BCLI) Misses Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- New leader board: Citi refreshes AI compute semiconductor picks
- Morgan Stanley continues to recommend exposure to the broadening theme
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
